Follow
Jorma Paavonen
Jorma Paavonen
Professori emeritus, Helsingin yliopisto
Verified email at helsinki.fi
Title
Cited by
Cited by
Year
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a …
J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ...
The Lancet 374 (9686), 301-314, 2009
20712009
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of …
J Paavonen, D Jenkins, FX Bosch, P Naud, J Salmerón, CM Wheeler, ...
The Lancet 369 (9580), 2161-2170, 2007
16782007
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection
LA Koutsky, KK Holmes, CW Critchlow, CE Stevens, J Paavonen, ...
New England journal of medicine 327 (18), 1272-1278, 1992
13931992
Once-daily valacyclovir to reduce the risk of transmission of genital herpes
L Corey, A Wald, R Patel, SL Sacks, SK Tyring, T Warren, JM Douglas Jr, ...
New England Journal of Medicine 350 (1), 11-20, 2004
9432004
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double …
M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ...
The lancet oncology 13 (1), 89-99, 2012
8972012
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined …
EA Joura, S Leodolter, M Hernandez-Avila, CM Wheeler, G Perez, ...
The Lancet 369 (9574), 1693-1702, 2007
8372007
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
LL Villa, RLR Costa, CA Petta, RP Andrade, J Paavonen, OE Iversen, ...
British Journal of Cancer 95 (11), 1459-1466, 2006
7452006
Chlamydia trachomatis: impact on human reproduction
J Paavonen, W Eggert-Kruse
Human reproduction update 5 (5), 433-447, 1999
7251999
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in …
DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ...
The Journal of infectious diseases 199 (7), 926-935, 2009
6962009
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma
T Anttila, P Saikku, P Koskela, A Bloigu, J Dillner, I Ikäheimo, E Jellum, ...
Jama 285 (1), 47-51, 2001
6372001
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis …
CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ...
The lancet oncology 13 (1), 100-110, 2012
6142012
Pelvic inflammatory disease
RC Brunham, SL Gottlieb, J Paavonen
New England Journal of Medicine 372 (21), 2039-2048, 2015
5662015
Mucopurulent cervicitis—the ignored counterpart in women of urethritis in men
RC Brunham, J Paavonen, CE Stevens, N Kiviat, CC Kuo, CW Critchlow, ...
New England journal of medicine 311 (1), 1-6, 1984
4871984
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women
N Muñoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ...
Journal of the National Cancer Institute 102 (5), 325-339, 2010
4762010
Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up
R Hurskainen, J Teperi, P Rissanen, AM Aalto, S Grenman, A Kivelä, ...
Jama 291 (12), 1456-1463, 2004
4592004
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer
P Koskela, T Anttila, T Bjørge, A Brunsvig, J Dillner, M Hakama, ...
International journal of cancer 85 (1), 35-39, 2000
4302000
Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial
R Hurskainen, J Teperi, P Rissanen, AM Aalto, S Grenman, A Kivelä, ...
The Lancet 357 (9252), 273-277, 2001
4292001
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions
SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, ...
Cancer prevention research 2 (10), 868-878, 2009
4192009
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data
EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez, KA Ault, WK Huh, ...
Bmj 344, 2012
4142012
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
SE Olsson, LL Villa, RLR Costa, CA Petta, RP Andrade, C Malm, ...
Vaccine 25 (26), 4931-4939, 2007
4062007
The system can't perform the operation now. Try again later.
Articles 1–20